Imricor Medical Systems (ASX:IMR): US MRI-Guided Cardiac Programme Expands in 2026

Aditi Sarkar

12 November 2026 04:39 PM AEDT

Imricor Medical Systems (ASX:IMR): US MRI-Guided Cardiac Programme Expands in 2026

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Imricor (ASX:IMR) announced its first commercial US hospital customer in September 2026.
Rady Children’s Hospital-San Diego is establishing an MRI-guided cardiac programme.
NorthStar and Vision-MR received US regulatory clearances during 2026.
A Philips collaboration introduced a cardiac interventional MR laboratory configuration.

Imricor Medical Systems, Inc. (ASX:IMR) develops equipment and consumables for cardiac procedures guided by magnetic resonance imaging, including electrophysiology and catheter-based interventions. On 12 November 2026, its shares traded at AUD 1.31, up 3.15% for the session. Several 2026 product clearances and commercial announcements have extended the scope of its US activities, including a hospital programme and an interventional MRI laboratory solution. Regulatory access and installations remain different from completed procedures and recognised revenue.

MRI-Guided Cardiac Technology

Imricor (ASX:IMR) designs technologies intended for use inside an MRI environment, including the NorthStar mapping system and Vision-MR diagnostic catheter. Conventional cardiac procedures often use X-ray guidance; MRI-guided workflows use magnetic resonance imaging to provide anatomical information during interventions. The products have distinct functions, and medical procedures require compatible equipment and trained clinical teams. Imricor’s Business includes systems and consumables, so its potential Revenue streams depend on system placement, procedure activity and purchases of related products. Clinical Utility and commercial scale should be assessed separately.

US Regulatory and Commercial Milestones

During 2026, Imricor (ASX:IMR) announced US Food and Drug Administration clearances for its Vision-MR diagnostic catheter and NorthStar mapping system. Further clearances extended the indicated use of specified products to paediatric patients. In August, the company introduced its Imricor Cardiovascular business offering for MRI-guided cardiac catheterisation. In September, it announced Rady Children’s Hospital-San Diego as the first commercial US hospital customer for this offering. These milestones mark regulatory and commercial steps but do not establish how many future procedures will occur at each site.

Philips Collaboration and Laboratory Configuration

In August 2026, Imricor (ASX:IMR) and Philips announced an interventional MR laboratory solution combining a Philips 1.5-tesla MRI system with Imricor’s compatible products and workflow tools. The configuration is designed to support cardiac interventions in an MRI environment. Hospital adoption involves equipment planning, safety procedures, clinician Training and facility-specific workflows. The announcement identifies a commercial configuration; it should not be treated as evidence that every Philips MRI installation can immediately support the same procedures or that all hospitals have committed to purchase the equipment.

Financial and Operational Measurement

Imricor (ASX:IMR) published half-year 2026 financial results and quarterly activity disclosures through its investor reporting channel. For interpreting commercial progress, relevant measures include receipts from customers, operating payments, available cash and whether new programmes generate repeated consumable demand. Regulatory clearance enables Marketing within the authorised scope but does not represent a recognised sale. Neither hospital announcements nor product launches should be converted into estimated Earnings without disclosed contract terms and actual financial reporting. Equipment deployment can also involve a gap between ordering, installation and regular clinical use.

Risks and What to Watch Next

Imricor (ASX:IMR) operates in a regulated medical-device market where further product development, clinical training, hospital procurement and technical compatibility influence rollout. Changes in approval requirements or delays in specialist Facility preparation could affect implementation. Future reporting may clarify the commissioning of US sites, procedure volumes, consumables consumption and additional customer contracts. These metrics can be considered alongside cash expenditure and any subsequently disclosed Capital requirements rather than assuming a rapid commercial conversion from announced milestones.

Key Insights

Imricor (ASX:IMR) reported several 2026 developments involving regulatory clearances, a US hospital customer and a Philips-compatible interventional MRI solution. Those disclosures describe meaningful operational stages but cannot on their own quantify revenue or profit. The progression from approval to installed systems and routine procedures remains an important subject for future updates.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.